Nash, P., Coates, L., Kivitz, A., Mease, P., Gladman, D., Covarrubias-Cobos, J., . . . Kanik, K. (2018). Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: Data from the third interim analysis of opal balance, an open-label, long-term extension study. BMJ Publishing Group Limited.
توثيق أسلوب شيكاغو (الطبعة السابعة عشر)Nash, P., et al. Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, Up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of Opal Balance, an Open-label, Long-term Extension Study. BMJ Publishing Group Limited, 2018.
توثيق جمعية اللغة المعاصرة MLA (الإصدار التاسع)Nash, P., et al. Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, Up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of Opal Balance, an Open-label, Long-term Extension Study. BMJ Publishing Group Limited, 2018.